11 results on '"Marchiori F."'
Search Results
2. OP0163 2019 UPDATE OF THE JOINT EUROPEAN LEAGUE AGAINST RHEUMATISM AND EUROPEAN RENAL ASSOCIATION–EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE MANAGEMENT OF LUPUS NEPHRITIS
- Author
-
Fanouriakis, A., primary, Kostopoulou, M., additional, Cheema, K., additional, Anders, H. J., additional, Aringer, M., additional, Bajema, I., additional, Boletis, J. N., additional, Frangou, E., additional, Houssiau, F., additional, Hollis, J., additional, Karras, A., additional, Marchiori, F., additional, Marks, S., additional, Moroni, G., additional, Mosca, M., additional, Parodis, I., additional, Praga, M., additional, Schneider, M., additional, Smolen, J. S., additional, Tesar, V., additional, Trachana, M., additional, Vollenhoven, R. V., additional, Voskuyl, A., additional, Teng, Y. K. O., additional, Van Leeuw, B., additional, Bertsias, G., additional, Jayne, D., additional, and Boumpas, D., additional
- Published
- 2020
- Full Text
- View/download PDF
3. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome
- Author
-
Andreoli, L, primary, Bertsias, G K, additional, Agmon-Levin, N, additional, Brown, S, additional, Cervera, R, additional, Costedoat-Chalumeau, N, additional, Doria, A, additional, Fischer-Betz, R, additional, Forger, F, additional, Moraes-Fontes, M F, additional, Khamashta, M, additional, King, J, additional, Lojacono, A, additional, Marchiori, F, additional, Meroni, P L, additional, Mosca, M, additional, Motta, M, additional, Ostensen, M, additional, Pamfil, C, additional, Raio, L, additional, Schneider, M, additional, Svenungsson, E, additional, Tektonidou, M, additional, Yavuz, S, additional, Boumpas, D, additional, and Tincani, A, additional
- Published
- 2016
- Full Text
- View/download PDF
4. LUPUS100.ORG A NEW TOOL FOR DOCTORS TO BUILD PATIENTS LUPUS KNOWLEDGE AND FIGHT POOR QUALITY WEB INFORMATION.
- Author
-
Cornet, A., Sluijmers, A., Marchiori, F., Hjelmeset, C., Povilaite, I. D., Koskina, E., and Sporre, K. Blomkvist
- Published
- 2023
- Full Text
- View/download PDF
5. ASSOCIATION BETWEEN DIAGNOSIS DELAY AND DISEASE ACTIVITY WITH BURDEN OF THE DISEASE IN 4150 EUROPEAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.
- Author
-
Cornet, A., Andersen, J., Marchiori, F., Sturiene, A., Edwards, A., Mertz, P., and Arnaud, L.
- Published
- 2023
- Full Text
- View/download PDF
6. PATIENT-DOCTOR COMMUNICATION GAP - RESULTS OF A SPEED-SHOP ON "LUPUS FLARE" AT LUPUS2022 MEETINGS.
- Author
-
Cornet, A., Marchiori, F., Stefánsdóttir, H., and Mosca, M.
- Published
- 2023
- Full Text
- View/download PDF
7. OP0086 Eular Recommendations for Women's Health and the Management of Family Planning, Assisted Reproduction, Pregnancy, and Menopause in Patients With Systemic Lupus Erythematosus and/or the Antiphospholipid Syndrome
- Author
-
Andreoli, L., primary, Bertsias, G., additional, Agmon-Levin, N., additional, Brown, S., additional, Cervera, R., additional, Costedoat-Chalumeau, N., additional, Doria, A., additional, Fischer-Betz, R., additional, Forger, F., additional, Moraes-Fontes, M., additional, Khamashta, M., additional, King, J., additional, Lojacono, A., additional, Marchiori, F., additional, Meroni, P., additional, Mosca, M., additional, Motta, M., additional, Ostensen, M., additional, Pamfil, C., additional, Raio, L., additional, Schneider, M., additional, Svenungsson, E., additional, Tektonidou, M., additional, Yavuz, S., additional, Boumpas, D., additional, and Tincani, A., additional
- Published
- 2015
- Full Text
- View/download PDF
8. Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake.
- Author
-
Loza E, Carmona L, Woolf A, Fautrel B, Courvoisier DS, Verstappen S, Aarrestad Provan S, Boonen A, Vliet Vlieland T, Marchiori F, Jasinski T, Van der Elst K, Ndosi M, Dziedzic K, and Carrasco JM
- Subjects
- Delivery of Health Care, Humans, Research Design, Musculoskeletal Diseases diagnosis, Musculoskeletal Diseases therapy, Rheumatic Diseases diagnosis, Rheumatic Diseases therapy, Rheumatology
- Abstract
A clinical guideline is a document with the aim of guiding decisions based on evidence regarding diagnosis, management and treatment in specific areas of healthcare. Specific to rheumatic and musculoskeletal diseases (RMDs), adherence to clinical guidelines recommendations impacts the outcomes of people with these diseases. However, currently, the implementation of recommendations is less than optimal in rheumatology.The WHO has described the implementation of evidence-based recommendations as one of the greatest challenges facing the global health community and has identified the importance of scaling up these recommendations. But closing the evidence-to-practice gap is often complex, time-consuming and difficult. In this context, the implementation science offers a framework to overcome this scenario.This article describes the principles of implementation science to facilitate and optimise the implementation of clinical recommendations in RMDs. Embedding implementation science methods and techniques into recommendation development and daily practice can help maximise the likelihood that implementation is successful in improving the quality of healthcare and healthcare services., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
9. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
- Author
-
Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, Boumpas DT, Brodin N, Bruce IN, González-Gay MÁ, Jacobsen S, Kerekes G, Marchiori F, Mukhtyar C, Ramos-Casals M, Sattar N, Schreiber K, Sciascia S, Svenungsson E, Szekanecz Z, Tausche AK, Tyndall A, van Halm V, Voskuyl A, Macfarlane GJ, Ward MM, Nurmohamed MT, and Tektonidou MG
- Subjects
- Heart Disease Risk Factors, Humans, Risk Factors, Uric Acid, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome drug therapy, Cardiovascular Diseases etiology, Cardiovascular Diseases prevention & control, Gout complications, Lupus Erythematosus, Systemic diagnosis, Mixed Connective Tissue Disease complications, Musculoskeletal Diseases, Myositis, Rheumatic Diseases complications, Rheumatic Diseases drug therapy, Scleroderma, Systemic complications, Sjogren's Syndrome complications, Vasculitis complications
- Abstract
Objective: To develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS)., Methods: Following European League against Rheumatism (EULAR) standardised procedures, a multidisciplinary task force formulated recommendations for CVR prediction and management based on systematic literature reviews and expert opinion., Results: Four overarching principles emphasising the need of regular screening and management of modifiable CVR factors and patient education were endorsed. Nineteen recommendations (eleven for gout, vasculitis, SSc, MCTD, myositis, SS; eight for SLE, APS) were developed covering three topics: (1) CVR prediction tools; (2) interventions on traditional CVR factors and (3) interventions on disease-related CVR factors. Several statements relied on expert opinion because high-quality evidence was lacking. Use of generic CVR prediction tools is recommended due to lack of validated rheumatic diseases-specific tools. Diuretics should be avoided in gout and beta-blockers in SSc, and a blood pressure target <130/80 mm Hg should be considered in SLE. Lipid management should follow general population guidelines, and antiplatelet use in SLE, APS and large-vessel vasculitis should follow prior EULAR recommendations. A serum uric acid level <0.36 mmol/L (<6 mg/dL) in gout, and disease activity control and glucocorticoid dose minimisation in SLE and vasculitis, are recommended. Hydroxychloroquine is recommended in SLE because it may also reduce CVR, while no particular immunosuppressive treatment in SLE or urate-lowering therapy in gout has been associated with CVR lowering., Conclusion: These recommendations can guide clinical practice and future research for improving CVR management in rheumatic and musculoskeletal diseases., Competing Interests: Competing interests: GCD, DV, EH, LB, SB, DTB, NB, GK, FM, CM, MR-C, KS, SS, VPvH, GJM, MMW and MN have nothing to declare. FA: research grants from BMS, Celgene, Novartis and Sandoz and consulting fees from AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer and Sanofi-Aventis, all unrelated to this manuscript; INB: grant from GSK paid to institution, consulting fees from Astra Zeneca, GSK, Eli lilly, UC, MSD paid to institution, support for attending meetings and/or travel from GSK, participation on a data safety monitoring board/or advisory board from Aurinia, Astra Zeneca and ILTOO paid to institution, all unrelated to this manuscript; MÁG-G: grants/research support from AbbVie, MSD, Jansen and Roche paid to institution and personal consulting fees/participation in company sponsored speakers bureau from AbbVie, Pfizer, Roche, Celgene, MSD, Novartis, SOBI and Sanofi, all unrelated to this manuscript; SJ: grants from BMS paid to institution, personal consulting fees from Astra Zeneca, and personal fees from Danish Medicolegal Council, all unrelated to this manuscript; NS: grants paid to institution from Astrazeneca, Boehringer Ingelheim and Roche Diagnostics, personal consulting fees from Afimmune, Amgen, Astrazeneca, Boehringer Ingelheim, Eli-Lilly, Hanmi Pharamceuticals, MSD, Novartis, Novo Nordisk, Pfizer and Sanofi, all unrelated to this manuscript; ES: grant from Merck and honoraria from Janssen, all unrelated to this manuscript; ZS: research grants from Pfizer paid to institution and personal consulting fees from Pfizer, MSD, Lilly, Novartis, Roche, Gedeon Richter, Boehringer Ingelheim, Abbvie, all unrelated to this manuscript; A-KT: speakers fee from Berlin Chemie Menarini, Novarti and personal fees and non-financial support from AstraZeneca and Grünenthal, all unrelated to this manuscript; AT: consulting fees from Magenta Therapeutics and personal fees from Novartis and Idorsia for participation on a Data Safety Monitoring Board or Advisory Board, all unrelated to this manuscript; AV: personal consulting fees from Astra Zeneca and GS, all unrelated to this manuscript; MGT: research grants from Genesis, GSK, MSD, Pfizer and UCB paid to institution, and personal consulting fees from Genesis, GSK and Novartis, all unrelated to this manuscript., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
10. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
- Author
-
Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, and Boumpas DT
- Subjects
- Antirheumatic Agents therapeutic use, Azathioprine therapeutic use, Calcineurin Inhibitors therapeutic use, Drug Therapy, Combination, Europe, Glomerular Filtration Rate, Glucocorticoids therapeutic use, Humans, Hydroxychloroquine therapeutic use, Kidney Failure, Chronic etiology, Kidney Failure, Chronic therapy, Lupus Nephritis complications, Lupus Nephritis pathology, Lupus Nephritis physiopathology, Mycophenolic Acid therapeutic use, Proteinuria etiology, Proteinuria therapy, Immunosuppressive Agents therapeutic use, Lupus Nephritis drug therapy, Societies, Medical
- Abstract
Objective: To update the 2012 EULAR/ERA-EDTA recommendations for the management of lupus nephritis (LN)., Methods: Following the EULAR standardised operating procedures, a systematic literature review was performed. Members of a multidisciplinary Task Force voted independently on their level of agreeement with the formed statements., Results: The changes include recommendations for treatment targets, use of glucocorticoids and calcineurin inhibitors (CNIs) and management of end-stage kidney disease (ESKD). The target of therapy is complete response (proteinuria <0.5-0.7 g/24 hours with (near-)normal glomerular filtration rate) by 12 months, but this can be extended in patients with baseline nephrotic-range proteinuria. Hydroxychloroquine is recommended with regular ophthalmological monitoring. In active proliferative LN, initial (induction) treatment with mycophenolate mofetil (MMF 2-3 g/day or mycophenolic acid (MPA) at equivalent dose) or low-dose intravenous cyclophosphamide (CY; 500 mg × 6 biweekly doses), both combined with glucocorticoids (pulses of intravenous methylprednisolone, then oral prednisone 0.3-0.5 mg/kg/day) is recommended. MMF/CNI (especially tacrolimus) combination and high-dose CY are alternatives, for patients with nephrotic-range proteinuria and adverse prognostic factors. Subsequent long-term maintenance treatment with MMF or azathioprine should follow, with no or low-dose (<7.5 mg/day) glucocorticoids. The choice of agent depends on the initial regimen and plans for pregnancy. In non-responding disease, switch of induction regimens or rituximab are recommended. In pure membranous LN with nephrotic-range proteinuria or proteinuria >1 g/24 hours despite renin-angiotensin-aldosterone blockade, MMF in combination with glucocorticoids is preferred. Assessment for kidney and extra-renal disease activity, and management of comorbidities is lifelong with repeat kidney biopsy in cases of incomplete response or nephritic flares. In ESKD, transplantation is the preferred kidney replacement option with immunosuppression guided by transplant protocols and/or extra-renal manifestations. Treatment of LN in children follows the same principles as adult disease., Conclusions: We have updated the EULAR recommendations for the management of LN to facilitate homogenization of patient care., Competing Interests: Competing interests: AF reports personal fees from GSK, Abbvie, Amgen, Enorasis, Roche and Genesis Pharma, outside the submitted work. HJA reports personal fees from GSK, Astra Zeneca and Janssen, during the conduct of the study; personal fees from Secarna, Inositec, Previpharma and Noxxon, outside the submitted work. MA reports honoraria fees from GSK and Roche, outside the submitted work; FH reports honoraria fees from GSL, outside the submitted work. MP reports personal fees from Otsuka, grants and personal fees from Alexion, personal fees from Retrophin, outside the submitted work. YKOT reports grants from GSK, personal fees from Aurinia Pharmaceuticals, personal fees from Novartis, during the conduct of the study. MT reports grants from Abbvie, BMS, Novartis, Pfize and Roche and honoraria fees from Novartis, outside the submitted work. DJ reports personal fees from Astra-Zeneca, Aurinia, Boehringer-Ingelheim, grants and personal fees from Chemocentryx, GSK, Roche/Genentech, and Sanofi-Genzyme, personal fees and other from Vifor, outside the submitted work., (© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
11. EULAR recommendations for the management of antiphospholipid syndrome in adults.
- Author
-
Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, and Ward MM
- Subjects
- Adult, Antibodies, Antiphospholipid blood, Anticoagulants therapeutic use, Female, Humans, Male, Pregnancy, Pregnancy Complications blood, Pregnancy Complications immunology, Risk Factors, Venous Thrombosis immunology, Antiphospholipid Syndrome blood, Antiphospholipid Syndrome immunology, Practice Guidelines as Topic, Rheumatology standards
- Abstract
The objective was to develop evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature review and expert opinion, overarching principles and recommendations were formulated and voted. High-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS. Risk modification includes screening for and management of cardiovascular and venous thrombosis risk factors, patient education about treatment adherence, and lifestyle counselling. Low-dose aspirin (LDA) is recommended for asymptomatic aPL carriers, patients with systemic lupus erythematosus without prior thrombotic or obstetric APS, and non-pregnant women with a history of obstetric APS only, all with high-risk aPL profiles. Patients with APS and first unprovoked venous thrombosis should receive long-term treatment with vitamin K antagonists (VKA) with a target international normalised ratio (INR) of 2-3. In patients with APS with first arterial thrombosis, treatment with VKA with INR 2-3 or INR 3-4 is recommended, considering the individual's bleeding/thrombosis risk. Rivaroxaban should not be used in patients with APS with triple aPL positivity. For patients with recurrent arterial or venous thrombosis despite adequate treatment, addition of LDA, increase of INR target to 3-4 or switch to low molecular weight heparin may be considered. In women with prior obstetric APS, combination treatment with LDA and prophylactic dosage heparin during pregnancy is recommended. In patients with recurrent pregnancy complications, increase of heparin to therapeutic dose, addition of hydroxychloroquine or addition of low-dose prednisolone in the first trimester may be considered. These recommendations aim to guide treatment in adults with APS. High-quality evidence is limited, indicating a need for more research., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.